It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What ...

Core Insights - The U.S. medical instrument and medtech sector is stabilizing as it enters 2026, with normalized procedure volumes post-pandemic and a focus on productivity and cost management [1][3] - Companies that can demonstrate operational improvements and earnings visibility are favored in the current investment environment, despite modest top-line growth [1][6] U.S. Macro Trends - Medtech equities are influenced by U.S. macroeconomic factors, particularly the Federal Reserve's interest rate policy, which is currently targeted between 3.5% and 3.75% [3] - Elevated labor and materials inflation rates have moderated, impacting margins more than demand, as companies align pricing and productivity with cost structures [4] Hospital Dynamics - U.S. hospitals are managing tight capital budgets while maintaining steady procedure volumes, benefiting companies with strong service and consumables revenue rather than those reliant on large equipment sales [5] - Staffing shortages are driving hospitals towards automation and efficiency, creating opportunities for device manufacturers offering productivity-enhancing solutions [5] Investment Opportunities in Undervalued Stocks - Undervalued medtech stocks may outperform through earnings recovery and multiple re-rating, as historical periods of uncertainty often compress valuations [6][7] - "Undervalued" stocks are defined as those trading below their historical valuation ranges, with potential for earnings growth through operational leverage and cost-reduction initiatives [7] Company-Specific Insights Fresenius Medical Care (FMS) - FMS is experiencing margin recovery due to cost savings and pricing improvements, with a current P/S F12M of 0.55x, below its 5-year median of 0.63x [10][11] - The company reported a rise in operating margin to 11.7% for Q3 2025, supported by cost savings and disciplined execution, with an expected earnings growth of 9% in 2026 [11][13] Integra LifeSciences (IART) - IART operates in neurosurgery and surgical instruments, currently trading at a P/S F12M of 0.59x, below its 5-year median of 2.14x [14][15] - The company anticipates supply normalization and margin expansion initiatives targeting $25-$30 million in savings, with expected earnings growth of 5.5% in 2026 [15][16] STERIS (STE) - STERIS provides sterilization services and is currently trading at a P/S F12M of 4.23x, slightly above its 5-year median of 3.97x [18][19] - The company reported high-single-digit organic revenue growth and expanded EBIT margin to 23.1%, with an expected earnings growth of 8.6% in 2026 [19][21]

Core Insights - The application of generative AI in the Medical Instruments industry has transitioned from experimental to operational, enhancing diagnostics, patient monitoring, and intervention workflows [1] - The global AI in healthcare market is projected to grow at a CAGR of 44% from 2025 to 2032, despite facing geopolitical challenges [2] - The medical instruments industry is highly fragmented, with significant trends including AI integration, telemedicine expansion, and robotic-assisted surgeries [3] Industry Trends - **Generative AI Adoption**: The medical instruments sector is experiencing a surge in generative AI adoption, with a focus on hyper-personalization and predictive treatment options. The global generative AI market in healthcare is valued at $2.64 billion in 2025, expected to grow at a CAGR of 35.2% through 2034 [4] - **M&A Activity**: The industry is witnessing a robust M&A trend, with MedTech deal value reaching $92.8 billion in 2025, driven by major acquisitions such as Abbott's $23 billion deal for Exact Sciences [5] - **Business Disruption**: Global growth is projected to remain subdued, with the IMF forecasting growth rates of 3.2% in 2025 and 3.1% in 2026, below pre-pandemic averages [6][7] Performance Metrics - The Zacks Medical Instruments industry currently holds a Zacks Industry Rank of 161, placing it in the bottom 33% of 243 Zacks industries, indicating poor near-term prospects [8] - The industry has underperformed the S&P 500 and broader sector over the past year, with a growth of 3.1% compared to the sector's 6.9% and the S&P 500's 19.3% [10] - The industry is trading at a forward P/E of 30.36X, higher than the broader industry average of 21.29X and the S&P 500's 23.42X [13] Company Highlights - **Veracyte**: A global cancer diagnostics company with a projected 2025 sales estimate of $508.6 million, reflecting a 14.1% increase from 2024 [18][19] - **IDEXX Laboratories**: Focused on veterinary and livestock testing, with a 2025 sales estimate of $4.28 billion, indicating a 9.9% rise from 2024 [21][22] - **Intuitive Surgical**: Specializes in minimally invasive care, with a 2025 sales estimate of $9.92 billion, suggesting an 18.7% increase from 2024 [25][26]

Core Insights - The replacement cycle for instruments has been ongoing for about a year, with significant momentum observed in orders outpacing revenues [1][2] - The growth rate for LC-MS instruments remains in the high single-digit range, driven by the replacement cycle and other factors [2][3] - The industry is still in the early stages of the replacement cycle, with many customer segments yet to begin replacing their instruments [3] Group 1 - The instrument replacement cycle is expected to continue, indicating a positive trend for future growth [3] - Current growth for LC-MS instruments is characterized by a low single-digit CAGR over the past six years, suggesting room for improvement [3] - The sales funnel for instruments is strong, indicating good future demand [3]

Company Overview - ChemoMetec A/S develops, manufactures, and markets instruments for cell counting and various other measurements, targeting the pharmaceutical, biotech, and agricultural industries globally [2] - The company was founded in 1997 and is listed on Nasdaq OMX Copenhagen [2] Managerial Transactions - The company has received a notification regarding transactions related to its shares made by persons in managerial positions, specifically mentioning CEO Martin Helbo Behrens [1]

Core Viewpoint - DexCom, Inc. is expected to report strong third-quarter results, driven by operational momentum, patient growth, and improved access, with a raised full-year revenue outlook reflecting confidence in demand and reimbursement expansion [1][2][8] Operational Performance - The company enters Q3 with solid operational momentum, supported by continued patient growth and a strengthening global footprint [2][8] - Commercial execution is a focal point, with healthy uptake of the product portfolio, particularly G7 and Stelo, despite competitive pressures [3][8] - Improved channel operations and access expansion are likely to have contributed to stronger prescription trends and pharmacy channel throughput [4][6] U.S. Market Dynamics - Strong new patient additions and integration with over 100 health systems have supported smoother prescription workflows [4][5] - Coverage for Type 2 diabetes patients not on insulin has broadened, with access secured through a major PBM, potentially covering around six million lives [4][5] International Trends - The international business has maintained healthy growth, driven by expanding Type 2 access and market penetration in regions like Ontario, France, and Japan [7][10] - Management expects continued international contribution, supported by growing awareness among primary care providers and improving prescription visibility [9][10] Stelo and New Market Initiatives - Stelo is an emerging growth vector, with over 400,000 app downloads and partnerships enhancing user engagement [11][12] - While currently a small financial contributor, Stelo is expected to represent 2% to 3% of 2025 sales, with ongoing feature expansion likely to accelerate adoption [12] Financial Outlook and Margin Progress - The company raised its full-year 2025 revenue outlook to $4.60 to $4.625 billion, reflecting 14% to 15% growth [13] - Gross margin is projected at approximately 62%, with expectations for sequential improvement as freight costs ease and inventory levels normalize [13][14] Estimate Picture - The Zacks Consensus Estimate for Q3 revenues is $1.18 billion, indicating an 18.4% improvement year-over-year, with EPS expected to increase by 26.7% to 57 cents [15] Long-Term Investment Visibility - Dexcom's long-term growth is supported by the expansion of the CGM category into Type 2 and pre-diabetes markets, with improving coverage and digital workflow integration [24][25] - Innovation remains central to the strategy, with advancements in product offerings and software enhancing usability and user engagement [25][26]

Core Insights - Conestoga Capital Advisors reported that equity markets reached new all-time highs in Q3 2025, but their Mid Cap Composite underperformed with a return of -3.2% net-of-fees compared to a 2.8% gain for the Russell Midcap Growth Index [1] - The focus on high-quality, profitable companies struggled in a risk-on environment during the quarter [1] Company Overview: IDEXX Laboratories, Inc. - IDEXX Laboratories, Inc. is a leader in diagnostics and information systems for veterinary, food, and water testing applications [3] - The company reported a one-month return of -1.74% and a 52-week gain of 38.06%, with shares closing at $637.13 on October 21, 2025, and a market capitalization of $50.97 billion [2] - IDEXX's revenue increased by 11% as reported and 9% organically in Q2 2025, despite weak veterinarian visits [4] Performance and Market Position - IDEXX Laboratories experienced strong earnings in Q3 2025, with accelerated organic revenue growth and rapid adoption of their latest premium instrument [3] - The number of hedge funds holding IDEXX shares decreased from 51 to 48 from the previous quarter, indicating a slight decline in popularity among institutional investors [4]

Core Insights - Intuitive Surgical is poised for a potential breakout as it approaches its earnings report on October 21, 2025, driven by recent developments that enhance its growth outlook [1][2][3] Regulatory Developments - Recent FDA approvals and European expansion have significantly broadened Intuitive Surgical's addressable market, likely leading to increased adoption of its systems in the U.S. and internationally [2][5] - Speculation around key regulatory clearances, coupled with buying activity from U.S. Congress members, has led to a premium valuation for the company, indicating heightened growth expectations [3][8] Technological Advancements - The company is advancing artificial intelligence-driven robotics for surgical procedures, which allows for remote operations with high precision, creating competitive advantages that are difficult to breach [4][5] - The Ion endoluminal system trials have been cleared in both Europe and the U.S., involving over 2,000 subjects, which is expected to diversify and accelerate revenue growth [6] Market Sentiment - Intuitive Surgical's stock is currently trading at 70% of its 52-week high, presenting an attractive risk-to-reward ratio for investors [7] - Recent purchases by congressional members suggest insider confidence in the company's future prospects, particularly in light of upcoming earnings reports [8] Financial Performance - The company reported net earnings per share (EPS) of $2.19, exceeding the MarketBeat consensus of $1.93 by 13%, indicating strong financial performance [11] - Analyst consensus price target for the stock is $589.43, suggesting a 37.2% upside potential from the current trading price [10] Sector Performance - The Healthcare Select Sector SPDR Fund has underperformed the S&P 500 by approximately 22% over the past year, indicating a potential recovery opportunity for healthcare stocks, including Intuitive Surgical [12]

Core Points - The Annual General Meeting of ChemoMetec A/S was held on 9 October 2025, where the Board of Directors' report and the annual report for 2024/25 were approved [1] - A dividend of DKK 7 per share was approved for distribution [2] - The Board of Directors will continue to consist of 5 members, with Niels Thestrup, Martin Glensbjerg, Kristine Færch, Betina Hagerup, and Peter Reich re-elected [2] - Deloitte was re-elected as the company's auditor, and the remuneration report was approved [3] - The Board of Directors was granted authority to acquire treasury shares [3] - A statutory board meeting was held post-general meeting, re-electing Niels Thestrup as chairman and Martin Glensbjerg as deputy chairman [4] Company Overview - ChemoMetec develops, manufactures, and markets instruments for cell counting and various measurements, serving the pharmaceutical, biotech, and agricultural industries globally [5] - The company was founded in 1997 and is listed on Nasdaq OMX Copenhagen [6]

Market Overview - U.S. equity markets are showing mixed signals in premarket trading, with major indexes having closed at record highs previously, while futures indicate a cautious opening [1][2] - S&P 500 futures are up approximately 0.07% to 0.17%, and Nasdaq 100 futures are showing gains of around 0.19% to 0.36%, indicating confidence in the technology sector [2] - Dow Jones Industrial Average futures are slightly down by about 0.04% to 0.05%, while Russell 2000 futures are pointing higher with gains of 0.08% to 0.41% [2] Commodities and Cryptocurrencies - Gold futures are up 0.18%, nearing $3,900 per ounce, as investors seek safe haven assets amid market uncertainty [3] - Bitcoin has risen 1.78%, trading around $116,441 to $116,500, marking its highest level in two weeks [3] - The yield on the 10-year Treasury has slipped slightly to 4.10% [3] Recent Performance of Major Indexes - On October 1st, the S&P 500 climbed 0.3% to set a new all-time high, while the Dow Jones Industrial Average added 43 points, or 0.1%, reaching its second consecutive record close [4] - The Nasdaq Composite rose 0.4%, marking the strongest September for the S&P 500 in 15 years [4] Upcoming Market Events - Key economic data releases include August Factory Orders and Durable Goods Orders, along with the weekly Unemployment Claims report, expected to show a slight increase in claims [5] - Earnings reports are anticipated from companies such as AngioDynamics, Tesco, VinFast, and others, which will be closely scrutinized for their impact on market sentiment [5] - Federal Reserve officials' remarks, particularly from Dallas Fed's Lorie Logan, are expected to be impactful, with a 94.6% likelihood of an interest rate cut projected for the October meeting [5] Company-Specific Developments - Nike shares rose 6.4% after surpassing profit expectations and reporting strong growth in North American apparel sales [9] - Lithium Americas stock surged 23.3% after the U.S. government approved a $2.26 billion loan and took an ownership stake in the company, with a premarket climb of 39% [9] - Tesla is anticipated to report its third-quarter deliveries soon, following a four-session winning streak [9] - BASF announced new recycling processes for polyamides from end-of-life vehicles, contributing to the circular economy [9] - Unilever released a shareholder circular regarding a demerger expected to be finalized on November 8, 2025, which could impact its valuation and strategic direction [9] - Zurich Insurance Group published a report advocating for standardized national cybersecurity metrics to address global cyber risk protection gaps [9]